Coloplast’s Q2 2018 results came in above our estimates on the top line while under-performing our bottom-line estimates. Segment-wise, Ostomy and Continence care maintained momentum, Wound Care bounced back while Skin Care disappointed. The company remained confident of the current investment and cost rationalisation efforts paying off from 2019-20. We have nudged up our long-term margin estimates and forecasts, but maintain a reduce recommendation, and believe that the recent rally ha
29 May 2018
Healthy signals confirmed by a guidance upgrade
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Healthy signals confirmed by a guidance upgrade
Coloplast A/S Class B (COLO:WBO) | 0 0 1.7% | Mkt Cap: 103,237m
- Published:
29 May 2018 -
Author:
Kamla Singh -
Pages:
3
Coloplast’s Q2 2018 results came in above our estimates on the top line while under-performing our bottom-line estimates. Segment-wise, Ostomy and Continence care maintained momentum, Wound Care bounced back while Skin Care disappointed. The company remained confident of the current investment and cost rationalisation efforts paying off from 2019-20. We have nudged up our long-term margin estimates and forecasts, but maintain a reduce recommendation, and believe that the recent rally ha